GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Healthwell Acquisition Corp I (NAS:HWELW) » Definitions » Additional Paid-In Capital

HWELW (Healthwell Acquisition I) Additional Paid-In Capital : $0.00 Mil(As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Healthwell Acquisition I Additional Paid-In Capital?


Healthwell Acquisition I Additional Paid-In Capital Historical Data

The historical data trend for Healthwell Acquisition I's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healthwell Acquisition I Additional Paid-In Capital Chart

Healthwell Acquisition I Annual Data
Trend Dec21 Dec22
Additional Paid-In Capital
- -

Healthwell Acquisition I Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Healthwell Acquisition I Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Healthwell Acquisition I Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Healthwell Acquisition I's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Healthwell Acquisition I Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Healthwell Acquisition Corp I (NAS:HWELW) » Definitions » Additional Paid-In Capital
Comparable Companies
PWUP BLUA CBRG CHAA NNAG TGAA DPCS EGGF PORT CITE PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA
Traded in Other Exchanges
N/A
Address
1001 Green Bay Road, Suite 227, Winnetka, IL, USA, 60093
Website
https://www.healthwellspac.com
Healthwell Acquisition Corp I is a blank check company.

Healthwell Acquisition I Headlines

From GuruFocus

Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions

By Business Wire • 10-17-2023

Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate

By Business Wire • 11-18-2023

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire • 10-04-2023

Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments

By Business Wire Business Wire • 04-27-2023

Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.

By Business Wire • 11-04-2023

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

By Business Wire • 09-13-2023

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire • 07-10-2023

Healthwell Acquisition Corp. I Announces Closing of $250,000,000 Initial Public Offering

By Business Wire Business Wire • 08-05-2021

Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference

By Business Wire Business Wire • 06-06-2023

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire Business Wire • 06-12-2023